Clement C. Zai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clement C. Zai has a total of 885 co-authors. Here are the top co-authors by number of shared publications:
- James L. Kennedy
CAMH, University of Toronto
37 shared publications Arun K. Tiwari
Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
14 shared publications- Arun Kumar Tiwari
Tanenbaum Centre for Pharmacogenetics, Neurogenetics Section, Molecular Brain Sciences Research Department, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
13 shared publications Gary Remington
Tanenbaum Centre for Pharmacogenetics Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health Toronto Ontario Canada
9 shared publicationsJames L. Kennedy
Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
9 shared publicationsGwyneth C. Zai
Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
8 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Research Square
Polygenic Architecture and Molecular Pathways Underlying Methadone Treatment Response in Opioid Use Disorder: Evidence from an Iranian Cohort
Background Response to methadone maintenance therapy (MMT) varies widely, but its genetic basis remains poorly understood, particularly in non-European populations. We hypothesized that shared polygenic liability across psychiatric and substance use disorders contributes to earlier opioid use disorder (OUD) onset through specific pathways and predicts MMT response. Methods We analyzed 769 Iranian individuals with OUD receiving MMT. After quality control, subsets were used to: (i) test polygenic risk scores (PRS) for psychiatric, substance-use, and antidepressant response traits; and (ii) perform a genome-wide association study (GWAS) for both age of onset and methadone response, integrating locus-specific fine-mapping and MAGMA gene-based and pathway enrichment analyses. Results Higher MDD polygenic risk was associated with reduced odds of methadone treatment response and remained significant in a model jointly including bipolar disorder and schizophrenia PRSs; the latter PRSs were not independently significant. The age-of-onset of OUD GWAS identified a suggestive non-coding locus on chromosome 4 (β=−2.74, P = 1.69×10 − 6 ) and suggestive signals ( P = 1×10 − 5 to 5×10 − 5 ) near GLP1R , MAPK10 , PDE 4 B , TIA 1 and SNRPG. The methadone response GWAS identified suggestive loci in EPHA5 (OR = 1.81, P = 9.9×10 − 6 ) and HOMER1 (OR = 0.54, P = 1.6×10 − 5 ). Pathway analysis implicated branched-chain amino acid and fatty acid metabolism in age at onset (FDR<0.05), and TGF-β and JAK–STAT signaling in methadone response ( P =9.9×10⁻⁷–1.1×10⁻³; FDR<0.05). Conclusions Distinct but convergent polygenic and biological mechanisms shape opioid-use onset and methadone response, implicating psychiatric liability, metabolic regulation, and neuroimmune signaling as candidate mechanisms of clinical heterogeneity in OUD.
- 1 October 2026
- Published by Springer Nature in Research Square
Open AccessPolygenic Architecture and Molecular Pathways Underlying Methadone Treatment Response in Opioid Use Disorder: Evidence from an Iranian Cohort
Background Response to methadone maintenance therapy (MMT) varies widely, but its genetic basis remains poorly understood, particularly in non-European populations. We hypothesized that shared polygenic liability across psychiatric and substance use disorders contributes to earlier opioid use disorder (OUD) onset through specific pathways and predicts MMT response. Methods We analyzed 769 Iranian individuals with OUD receiving MMT. After quality control, subsets were used to: (i) test polygenic risk scores (PRS) for psychiatric, substance-use, and antidepressant response traits; and (ii) perform a genome-wide association study (GWAS) for both age of onset and methadone response, integrating locus-specific fine-mapping and MAGMA gene-based and pathway enrichment analyses. Results Higher MDD polygenic risk was associated with reduced odds of methadone treatment response and remained significant in a model jointly including bipolar disorder and schizophrenia PRSs; the latter PRSs were not independently significant. The age-of-onset of OUD GWAS identified a suggestive non-coding locus on chromosome 4 (β=−2.74, P = 1.69×10 − 6 ) and suggestive signals ( P = 1×10 − 5 to 5×10 − 5 ) near GLP1R , MAPK10 , PDE 4 B , TIA 1 and SNRPG. The methadone response GWAS identified suggestive loci in EPHA5 (OR = 1.81, P = 9.9×10 − 6 ) and HOMER1 (OR = 0.54, P = 1.6×10 − 5 ). Pathway analysis implicated branched-chain amino acid and fatty acid metabolism in age at onset (FDR<0.05), and TGF-β and JAK–STAT signaling in methadone response ( P =9.9×10⁻⁷–1.1×10⁻³; FDR<0.05). Conclusions Distinct but convergent polygenic and biological mechanisms shape opioid-use onset and methadone response, implicating psychiatric liability, metabolic regulation, and neuroimmune signaling as candidate mechanisms of clinical heterogeneity in OUD.
- Open Access
Two modes of aversive control in suicidality: joint computational modelling exposes regime-specific clinical signatures invisible to symptom-based stratification
1 Suicidal thoughts and behaviours (STBs) are heterogeneous in their proximal dynamics, planning, and stress-sensitivity, yet most subtyping efforts remain symptom-driven and rarely validated across independent datasets. Computational mixture modelling offers a principled alternative: by fitting explicit models of learning and action selection and partitioning individuals by their latent parameter profiles, it can identify mechanistically distinct control strategies invisible to cross-sectional symptom measurement. We applied this approach to aversive Go/NoGo performance, jointly clustering two independently collected STB-enriched samples (N = 50 and N = 184) using tasks with the same structure but different duration, reversal timing, and clinical instrumentation. Two recurrent behavioural regimes emerged: a fast/adaptive regime characterised by rapid policy updating and elevated feedback reactivity, and a slow/perseverative regime characterised by slow updating, high choice determinism, and a pronounced cost following contingency reversal. These regimes were stable across initialisations, recovered more parsimoniously in joint than independent solutions, and were largely orthogonal to symptom-based stratification. Critically, stratification by regime exposed clinical–computational coupling structures substantially attenuated in pooled analyses. Pooled, population-level associations were modest and anchored by a broad affective burden axis. Within the slow/perseverative regime, coupling reorganised around learning dynamics and internalizing burden (depression, hopelessness, and active suicidal ideation) with markedly larger effect sizes. Within the fast/adaptive regime, a dissociation between anxious–compulsive and antisocial–disinhibitory profiles emerged along the same computational axis, invisible at the population level. These findings support a view of suicidality heterogeneity in which clinically similar individuals differ in the control strategies they recruit under aversive uncertainty – variation that symptom measurement alone cannot capture.
Open AccessTwo modes of aversive control in suicidality: joint computational modelling exposes regime-specific clinical signatures invisible to symptom-based stratification
1 Suicidal thoughts and behaviours (STBs) are heterogeneous in their proximal dynamics, planning, and stress-sensitivity, yet most subtyping efforts remain symptom-driven and rarely validated across independent datasets. Computational mixture modelling offers a principled alternative: by fitting explicit models of learning and action selection and partitioning individuals by their latent parameter profiles, it can identify mechanistically distinct control strategies invisible to cross-sectional symptom measurement. We applied this approach to aversive Go/NoGo performance, jointly clustering two independently collected STB-enriched samples (N = 50 and N = 184) using tasks with the same structure but different duration, reversal timing, and clinical instrumentation. Two recurrent behavioural regimes emerged: a fast/adaptive regime characterised by rapid policy updating and elevated feedback reactivity, and a slow/perseverative regime characterised by slow updating, high choice determinism, and a pronounced cost following contingency reversal. These regimes were stable across initialisations, recovered more parsimoniously in joint than independent solutions, and were largely orthogonal to symptom-based stratification. Critically, stratification by regime exposed clinical–computational coupling structures substantially attenuated in pooled analyses. Pooled, population-level associations were modest and anchored by a broad affective burden axis. Within the slow/perseverative regime, coupling reorganised around learning dynamics and internalizing burden (depression, hopelessness, and active suicidal ideation) with markedly larger effect sizes. Within the fast/adaptive regime, a dissociation between anxious–compulsive and antisocial–disinhibitory profiles emerged along the same computational axis, invisible at the population level. These findings support a view of suicidality heterogeneity in which clinically similar individuals differ in the control strategies they recruit under aversive uncertainty – variation that symptom measurement alone cannot capture.
- 4 June 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (9) , 703-711
Distribution of Cytochrome P450 Metabolizer Status and Allelic Variants in Individuals with Mental Health Disorders in Ontario, Canada: Répartition du statut métabolique du cytochrome P450 et des variantes alléliques chez les personnes atteintes de problèmes de santé mentale en Ontario, au Canada
Introduction: Drug metabolism is primarily carried out by the cytochrome P450 (CYP) family of enzymes in the liver. Based on an individual's diplotype, they can be classified into poor (PM), intermediate (IM), normal (NM), rapid (RM) or ultrarapid (UM) metabolizers. Here, we show the distribution of allele frequency and metabolizer status across ancestries for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 in a cohort from Ontario, Canada. Methods: Patients currently taking or starting a psychotropic drug ( N = 8,280) were enrolled. Patients self-reported their ancestry, and DNA was analysed for the CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 genes using a commercial pharmacogenetic test and metabolizer status was assigned using ClinPGx as a reference. Results: The cohort was primarily of European ancestry (70%), followed by individuals with mixed ancestry (9.3%). The combined frequency of PMs and UMs, representing the extremes of enzyme activity, was highest for CYP2C19 and CYP2D6, with this frequency being approximately 8% for each enzyme. The frequency varied considerably by ancestry, with up to 24% of individuals of Caribbean descent being CYP2C19 PMs or UMs, for example, compared to only 7% among those of Latin, Central and South American ancestry. Of the entire sample, only 5.1% were NMs across all enzymes, meaning 94.9% of individuals had a non-NM status and would benefit from pharmacogenetic testing. Conclusion: Overall, this study provides a useful reference for variations in the CYP family of genes in the population of Ontario, Canada.
- 4 June 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (9) , 703-711
Distribution of Cytochrome P450 Metabolizer Status and Allelic Variants in Individuals with Mental Health Disorders in Ontario, Canada: Répartition du statut métabolique du cytochrome P450 et des variantes alléliques chez les personnes atteintes de problèmes de santé mentale en Ontario, au Canada
Introduction: Drug metabolism is primarily carried out by the cytochrome P450 (CYP) family of enzymes in the liver. Based on an individual's diplotype, they can be classified into poor (PM), intermediate (IM), normal (NM), rapid (RM) or ultrarapid (UM) metabolizers. Here, we show the distribution of allele frequency and metabolizer status across ancestries for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 in a cohort from Ontario, Canada. Methods: Patients currently taking or starting a psychotropic drug ( N = 8,280) were enrolled. Patients self-reported their ancestry, and DNA was analysed for the CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 genes using a commercial pharmacogenetic test and metabolizer status was assigned using ClinPGx as a reference. Results: The cohort was primarily of European ancestry (70%), followed by individuals with mixed ancestry (9.3%). The combined frequency of PMs and UMs, representing the extremes of enzyme activity, was highest for CYP2C19 and CYP2D6, with this frequency being approximately 8% for each enzyme. The frequency varied considerably by ancestry, with up to 24% of individuals of Caribbean descent being CYP2C19 PMs or UMs, for example, compared to only 7% among those of Latin, Central and South American ancestry. Of the entire sample, only 5.1% were NMs across all enzymes, meaning 94.9% of individuals had a non-NM status and would benefit from pharmacogenetic testing. Conclusion: Overall, this study provides a useful reference for variations in the CYP family of genes in the population of Ontario, Canada.
- 3 April 2026
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 27 (3-4) , 137-144
Genetics of tardive dyskinesia: a review of progress over the past decade
1. A proportion of schizophrenia patients receiving long-term antipsychotic drug treatment develop a movement disorder that primarily affects the orofacial regions called tardive dyskinesia (TD) [1...
- 3 April 2026
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 27 (3-4) , 137-144
Genetics of tardive dyskinesia: a review of progress over the past decade
1. A proportion of schizophrenia patients receiving long-term antipsychotic drug treatment develop a movement disorder that primarily affects the orofacial regions called tardive dyskinesia (TD) [1...
- Top Cited PapersOpen Access
- 3 February 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (2) , 275-288
Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability. Although distinct in their clinical presentations, they probably represent differential expressions of a dysregulated threat–response system. Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 out of the 58 associations replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism implicated in ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.
- 3 February 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (2) , 275-288
Top Cited PapersOpen AccessGenome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability. Although distinct in their clinical presentations, they probably represent differential expressions of a dysregulated threat–response system. Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 out of the 58 associations replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism implicated in ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.
- Open Access
- 20 October 2025
- Published by Springer Nature in Research Square
Greater Mitochondrial DNA Pathogenicity is Associated with Greater Regional Cerebral Blood Flow in Youth Bipolar Disorder
Mitochondrial dysfunction is implicated in the neuropathology of bipolar disorder (BD). Mitochondrial DNA (mtDNA) variants are associated with anomalous cerebral energy metabolism and with increased risk for BD. Little is known about the relevance of mtDNA to cerebral blood flow (CBF) in BD. Participants included 101 youth (BD, n = 56; Control group, n = 45; ages 13–20). The Miseq platform was used to sequence saliva mtDNA. The mtDNA-Server pipeline was used for variant calling and annotation. mtDNA common variants (i.e. minor allele frequency larger than 5%) were included in the analyses due to sample size. We generated an mtDNA variant functional impact (FI) score by performing functional analysis using Mutserve and summing across the MutPred, Selection Score, and MitoTool algorithms. CBF was measured using pseudo-continuous arterial spin labeling magnetic resonance imaging. Region of interest (ROI) analyses examined FI scores in relation to CBF in the anterior cingulate cortex (ACC) and global gray matter, controlling for age and sex. Voxel-based analyses were also conducted. In ROI analyses, higher mtDNA FI score was associated with higher ACC CBF in the overall sample (β = 0.20, p = 0.045). In voxel-based analyses, higher mtDNA FI score was associated with higher CBF in regions within the basal ganglia, frontal and parietal lobe, and cingulate within the overall sample and within the BD group. This study found that higher mtDNA FI score, putatively reflecting mtDNA pathogenicity, was associated with higher regional CBF among youth. Present findings add to the evidence that elevated CBF may be a compensatory mechanism in youth with BD.
- 20 October 2025
- Published by Springer Nature in Research Square
Open AccessGreater Mitochondrial DNA Pathogenicity is Associated with Greater Regional Cerebral Blood Flow in Youth Bipolar Disorder
Mitochondrial dysfunction is implicated in the neuropathology of bipolar disorder (BD). Mitochondrial DNA (mtDNA) variants are associated with anomalous cerebral energy metabolism and with increased risk for BD. Little is known about the relevance of mtDNA to cerebral blood flow (CBF) in BD. Participants included 101 youth (BD, n = 56; Control group, n = 45; ages 13–20). The Miseq platform was used to sequence saliva mtDNA. The mtDNA-Server pipeline was used for variant calling and annotation. mtDNA common variants (i.e. minor allele frequency larger than 5%) were included in the analyses due to sample size. We generated an mtDNA variant functional impact (FI) score by performing functional analysis using Mutserve and summing across the MutPred, Selection Score, and MitoTool algorithms. CBF was measured using pseudo-continuous arterial spin labeling magnetic resonance imaging. Region of interest (ROI) analyses examined FI scores in relation to CBF in the anterior cingulate cortex (ACC) and global gray matter, controlling for age and sex. Voxel-based analyses were also conducted. In ROI analyses, higher mtDNA FI score was associated with higher ACC CBF in the overall sample (β = 0.20, p = 0.045). In voxel-based analyses, higher mtDNA FI score was associated with higher CBF in regions within the basal ganglia, frontal and parietal lobe, and cingulate within the overall sample and within the BD group. This study found that higher mtDNA FI score, putatively reflecting mtDNA pathogenicity, was associated with higher regional CBF among youth. Present findings add to the evidence that elevated CBF may be a compensatory mechanism in youth with BD.
- Open Access
- 2 October 2025
- Published by Elsevier in Psychiatry Research
- Vol. 353, 116760
Defining and assessing international classification of disease suicidality phenotypes for genetic studies
- 2 October 2025
- Published by Elsevier in Psychiatry Research
- Vol. 353, 116760
Open AccessDefining and assessing international classification of disease suicidality phenotypes for genetic studies
- Open Access
- 25 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 6144-6154
Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group
Suicidality phenotypes, consisting of suicidal ideation (SI), suicide attempt (SA), and suicide death (SD), are all heritable but present unique challenges in genome-wide association studies (GWAS) due to their individual complexity, overlap with each other and with related self-harm phenotypes, and varying associations with psychiatric disorders. GWAS have uncovered several loci associated with suicidality phenotypes by meta-analyzing data from multiple cohorts. However, combining datasets from many research groups, where each group may use different study designs, phenotyping instruments, and definitions of suicidality phenotypes, presents challenges. Heterogeneity resulting from these differences can limit genetic discovery; harmonizing phenotype definitions to ensure consistency will greatly improve results. Here, we describe a standardized phenotyping protocol that draws on the expertise of a subgroup of clinicians, researchers, and experts from the Psychiatric Genomics Consortium Suicide Working Group to propose consensus definitions for SI, SA, and SD for genetic studies.
- 25 September 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (12) , 6144-6154
Open AccessDefining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group
Suicidality phenotypes, consisting of suicidal ideation (SI), suicide attempt (SA), and suicide death (SD), are all heritable but present unique challenges in genome-wide association studies (GWAS) due to their individual complexity, overlap with each other and with related self-harm phenotypes, and varying associations with psychiatric disorders. GWAS have uncovered several loci associated with suicidality phenotypes by meta-analyzing data from multiple cohorts. However, combining datasets from many research groups, where each group may use different study designs, phenotyping instruments, and definitions of suicidality phenotypes, presents challenges. Heterogeneity resulting from these differences can limit genetic discovery; harmonizing phenotype definitions to ensure consistency will greatly improve results. Here, we describe a standardized phenotyping protocol that draws on the expertise of a subgroup of clinicians, researchers, and experts from the Psychiatric Genomics Consortium Suicide Working Group to propose consensus definitions for SI, SA, and SD for genetic studies.
- Open Access
- 5 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 74-79
GenoStaR : An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype‐to‐phenotype translation, especially for the CYP enzyme family, which metabolizes 70–80% of clinically used drugs. To address this, we have developed GenoStaR, an R package that converts genotypes into star alleles and predicts the associated metabolizer status for major cytochrome P450 genes— CYP1A2 , CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 , and CYP3A5 . GenoStaR assigns star alleles using single‐nucleotide polymorphisms, insertion–deletion variants, and structural variants. Given genotype data, GenoStaR uses comprehensive allele definition tables to determine diplotypes, activity scores, and predicted metabolizer status. The tool accounts for complex scenarios, including CYP2D6 copy number variations, using a tiered matching strategy and structural variant detection. We evaluated GenoStaR using two datasets. The first from the Centre for Addiction and Mental Health Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study ( n = 8,287), which included genotyping data, along with star allele information from a commercial pharmacogenetic test. The second, the Toronto Schizophrenia sample ( n = 188), with in‐house genotype data and manually validated star alleles. GenoStaR achieved 100% concordance in diplotype calls across both datasets. GenoStaR offers a reliable, efficient, and accurate solution for converting genotypes into star alleles and predicting CYP‐related metabolizer status. Its performance on a large validation dataset highlights its potential to enhance pharmacogenomic testing in clinical settings.
- 5 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 74-79
Open AccessGenoStaR : An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype‐to‐phenotype translation, especially for the CYP enzyme family, which metabolizes 70–80% of clinically used drugs. To address this, we have developed GenoStaR, an R package that converts genotypes into star alleles and predicts the associated metabolizer status for major cytochrome P450 genes— CYP1A2 , CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 , and CYP3A5 . GenoStaR assigns star alleles using single‐nucleotide polymorphisms, insertion–deletion variants, and structural variants. Given genotype data, GenoStaR uses comprehensive allele definition tables to determine diplotypes, activity scores, and predicted metabolizer status. The tool accounts for complex scenarios, including CYP2D6 copy number variations, using a tiered matching strategy and structural variant detection. We evaluated GenoStaR using two datasets. The first from the Centre for Addiction and Mental Health Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study ( n = 8,287), which included genotyping data, along with star allele information from a commercial pharmacogenetic test. The second, the Toronto Schizophrenia sample ( n = 188), with in‐house genotype data and manually validated star alleles. GenoStaR achieved 100% concordance in diplotype calls across both datasets. GenoStaR offers a reliable, efficient, and accurate solution for converting genotypes into star alleles and predicting CYP‐related metabolizer status. Its performance on a large validation dataset highlights its potential to enhance pharmacogenomic testing in clinical settings.
- Open Access
- 27 March 2025
- Published by Springer Nature in Research Square
Examining mitochondrial genetic variation in obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) is a severe neuropsychiatric disorder with clear evidence of genetic vulnerability, although specific risk factors are not fully understood. Mitochondrial dysfunction has been implicated in other severe neuropsychiatric disorders, particularly through its role in oxidative stress, and thus merits exploration in OCD. Here we first examined the association of a set of 59 mitochondrial single nucleotide polymorphisms (SNPs) with OCD symptom severity. These SNPs are located inside 28 nuclear-encoded mitochondrial genes involved in oxidative phosphorylation, oxidative stress, mitochondrial biogenesis, inflammation, and apoptosis. We used linear regression to test for the association of this SNP set with symptom severity using the Yale-Brown Obsessive Compulsive Scale (YBOCS). We found a nominally significant association for rs3820189 in the 5’ of the MFN2 gene with YBOCS total score (N = 346; Puncorrected= 0.002). We also conducted gene-based and gene-set (pathway) analyses on nuclear-encoded mitochondrial genes and pathways with OCD risk using MAGMA. We found the gene ADCK1 to be associated with OCD (p = 0.00005, q = 0.05). No mitochondrial pathways were associated with OCD risk. To further examine mitochondrial genetic variation in OCD risk, we then examined mitochondrial (mt) DNA (mtDNA), the circular genome located inside each mitochondrion. We utilized the Toronto OCD sample (N = 215) and the 1000 Genome Project (N = 485) as healthy controls for discovery. For replication, we compared individual-level data from the Psychiatric Genomics Consortium (PGC) OCD Working Group release 2017 (N = 1691) with the Wellcome Trust sample (N = 2616) as controls. After data cleaning, 58 common mtDNA SNPs (minor allele frequency greater than 1%) were available for analysis. Meta-analysis across the significant mtDNA variants shared between both samples revealed five SNPs significantly associated with OCD risk which survived Nyholt correction: NC_012920.1:m.1719G > A (P = 1.489E-05), NC_012920.1:m.3010G > A (P = 2.423E-05), NC_012920.1:m.10398A > G (P = 3.172E-04), NC_012920.1:m.11914G > A (P = 6.085E-04) and NC_012920.1:m.6260G > A (P = 7.792E-04). To the best of our knowledge, this is the largest study to report the involvement of mitochondrial variants in OCD risk. Further investigations and validation of our findings are warranted.
- 27 March 2025
- Published by Springer Nature in Research Square
Open AccessExamining mitochondrial genetic variation in obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) is a severe neuropsychiatric disorder with clear evidence of genetic vulnerability, although specific risk factors are not fully understood. Mitochondrial dysfunction has been implicated in other severe neuropsychiatric disorders, particularly through its role in oxidative stress, and thus merits exploration in OCD. Here we first examined the association of a set of 59 mitochondrial single nucleotide polymorphisms (SNPs) with OCD symptom severity. These SNPs are located inside 28 nuclear-encoded mitochondrial genes involved in oxidative phosphorylation, oxidative stress, mitochondrial biogenesis, inflammation, and apoptosis. We used linear regression to test for the association of this SNP set with symptom severity using the Yale-Brown Obsessive Compulsive Scale (YBOCS). We found a nominally significant association for rs3820189 in the 5’ of the MFN2 gene with YBOCS total score (N = 346; Puncorrected= 0.002). We also conducted gene-based and gene-set (pathway) analyses on nuclear-encoded mitochondrial genes and pathways with OCD risk using MAGMA. We found the gene ADCK1 to be associated with OCD (p = 0.00005, q = 0.05). No mitochondrial pathways were associated with OCD risk. To further examine mitochondrial genetic variation in OCD risk, we then examined mitochondrial (mt) DNA (mtDNA), the circular genome located inside each mitochondrion. We utilized the Toronto OCD sample (N = 215) and the 1000 Genome Project (N = 485) as healthy controls for discovery. For replication, we compared individual-level data from the Psychiatric Genomics Consortium (PGC) OCD Working Group release 2017 (N = 1691) with the Wellcome Trust sample (N = 2616) as controls. After data cleaning, 58 common mtDNA SNPs (minor allele frequency greater than 1%) were available for analysis. Meta-analysis across the significant mtDNA variants shared between both samples revealed five SNPs significantly associated with OCD risk which survived Nyholt correction: NC_012920.1:m.1719G > A (P = 1.489E-05), NC_012920.1:m.3010G > A (P = 2.423E-05), NC_012920.1:m.10398A > G (P = 3.172E-04), NC_012920.1:m.11914G > A (P = 6.085E-04) and NC_012920.1:m.6260G > A (P = 7.792E-04). To the best of our knowledge, this is the largest study to report the involvement of mitochondrial variants in OCD risk. Further investigations and validation of our findings are warranted.